May 1, 2007
Alexion losses widen, horizon brightens
Executives at Cheshire-based bio-firm Alexion Pharmaceuticals hope the recent FDA approval of their Soliris drug to treat a rare blood disease will help them reverse the widening losses the company saw this quarter. First quarter losses grew to $32.7 million, up from $27.2 million in the year ago quarter, while losses per share and diluted share widened to 92 cents, from 88 cents in the first quarter a year ago. Revenue, however, grew substantially during the quarter to $6.3 million, up from the $800,000 reported in the previous first quarter.
WBJ Web Partners
Most Recent
Most Recent
0 Comments